Despite Humira’s decline and looming pricing pressure on Imbruvica, AbbVie’s stock is soaring 10% this year, outpacing the S&P 500. The company’s rebound hinges on blockbuster immunology drugs Skyrizi and Rinvoq, projected to generate over $31 billion this year—with no biosimilar threat until 2033. Beyond these hits, AbbVie’s future looks strong: a weight-loss therapy in development, plus a $10.9 billion acquisition of Apogee Therapeutics, bringing in zumilokibart—a promising eczema treatment with convenient dosing. With a deep pipeline and strategic moves, AbbVie is positioning itself for sustained growth, even as short-term headwinds persist.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
